Edesa Biotech, Inc. vs Enliven Therapeutics, Inc. — Valuation Comparison 2026
Access all valuation models for EDSA vs ELVN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →EDSA scores higher with a 3.9/10 quality rating vs ELVN's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Edesa Biotech, Inc. (EDSA) and Enliven Therapeutics, Inc. (ELVN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
EDSA currently trades at $7.86 with a QOC of 3.9/10, while ELVN trades at $40.65 with a QOC of 3.8/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).